<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F"><gtr:id>A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F</gtr:id><gtr:name>Epistem</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC1D7232-9B00-44B3-BBAA-ACB3381663DD"><gtr:id>EC1D7232-9B00-44B3-BBAA-ACB3381663DD</gtr:id><gtr:name>Blueberry Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E91EA92B-76A4-4BA2-BDB0-4978BC6F7E30"><gtr:id>E91EA92B-76A4-4BA2-BDB0-4978BC6F7E30</gtr:id><gtr:name>QUANTUMDX Group Limited</gtr:name><gtr:address><gtr:line1>International Centre for Life</gtr:line1><gtr:line2>Times Square</gtr:line2><gtr:postCode>NE1 4EP</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/826B7EC8-CAFE-47E4-8244-1112F9D191A9"><gtr:id>826B7EC8-CAFE-47E4-8244-1112F9D191A9</gtr:id><gtr:name>Elisha Systems Ltd</gtr:name><gtr:address><gtr:line1>Sigma House</gtr:line1><gtr:line2>Burlow</gtr:line2><gtr:postCode>SK17 9JB</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6C9378BD-AB1F-401F-B4C2-77A7B846ED79"><gtr:id>6C9378BD-AB1F-401F-B4C2-77A7B846ED79</gtr:id><gtr:name>Godrej Consumer Products Limited</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB2319AB-8EEB-445A-8BB6-43D47D979CA9"><gtr:id>BB2319AB-8EEB-445A-8BB6-43D47D979CA9</gtr:id><gtr:name>Biomedical Primate Research Centre</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F"><gtr:id>A19DEFFA-FECA-4E87-B8C6-A2BC9F43550F</gtr:id><gtr:name>Epistem</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC1D7232-9B00-44B3-BBAA-ACB3381663DD"><gtr:id>EC1D7232-9B00-44B3-BBAA-ACB3381663DD</gtr:id><gtr:name>Blueberry Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E91EA92B-76A4-4BA2-BDB0-4978BC6F7E30"><gtr:id>E91EA92B-76A4-4BA2-BDB0-4978BC6F7E30</gtr:id><gtr:name>QUANTUMDX Group Limited</gtr:name><gtr:address><gtr:line1>International Centre for Life</gtr:line1><gtr:line2>Times Square</gtr:line2><gtr:postCode>NE1 4EP</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAA77269-CB2A-42CE-81EF-0E594636D7A2"><gtr:id>FAA77269-CB2A-42CE-81EF-0E594636D7A2</gtr:id><gtr:name>Avacta Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/826B7EC8-CAFE-47E4-8244-1112F9D191A9"><gtr:id>826B7EC8-CAFE-47E4-8244-1112F9D191A9</gtr:id><gtr:name>Elisha Systems Ltd</gtr:name><gtr:address><gtr:line1>Sigma House</gtr:line1><gtr:line2>Burlow</gtr:line2><gtr:postCode>SK17 9JB</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6C9378BD-AB1F-401F-B4C2-77A7B846ED79"><gtr:id>6C9378BD-AB1F-401F-B4C2-77A7B846ED79</gtr:id><gtr:name>Godrej Consumer Products Limited</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB2319AB-8EEB-445A-8BB6-43D47D979CA9"><gtr:id>BB2319AB-8EEB-445A-8BB6-43D47D979CA9</gtr:id><gtr:name>Biomedical Primate Research Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/35C0CE50-61C8-4951-A6BD-C121ABC82F8E"><gtr:id>35C0CE50-61C8-4951-A6BD-C121ABC82F8E</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13069"><gtr:id>6BBE6571-76E8-4189-B2D2-804169E5C10E</gtr:id><gtr:title>Liverpool School of Tropical Medicine Confidence in Concept 2013</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13069</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>500000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Avacta Group</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Avacta</gtr:description><gtr:id>B9457700-3E10-4D88-AC95-B4CD5BA63403</gtr:id><gtr:impact>Confidentiality agreement</gtr:impact><gtr:outcomeId>57dbb62589fe62.08390005-1</gtr:outcomeId><gtr:partnerContribution>Avacta are preparing MOU and in IP nergotiations to prepare the ground for funding of a venom reserach project</gtr:partnerContribution><gtr:piContribution>Contacts made following Adhiron CiC project and meeting held in Leeds for networking Adhiron technology. Avacta have interests in venoms,thus connections made with Dr Harrison and Venom Research Unit to develop reserach project</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Jenner Institute</gtr:department><gtr:description>Generation of human monoclonal antibodies against malarial antigens</gtr:description><gtr:id>F71B8713-74B4-4588-97E5-389E9976A0D1</gtr:id><gtr:impact>Generation of five recombinant monoclonal antibodies that cross-react with variants of the DBLb domain of PfEMP1</gtr:impact><gtr:outcomeId>56a6290517fa47.49915336-1</gtr:outcomeId><gtr:partnerContribution>Exchange of techniques for the generation of recombinant monoclonal antibodies</gtr:partnerContribution><gtr:piContribution>Exchange of techniques for the generation of recombinant monoclonal antibodies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaborators on the 'TB subunit vaccines' project</gtr:description><gtr:id>23C0943C-BEEF-495C-B39B-B8271E848473</gtr:id><gtr:impact>Applications for follow-on funding have been made - these were not successful but future funding will be sought.
Presentations of the research so far have been made.
The collaboration is multi-disciplinary in the fields of bioinformatics, pre-clinical vaccinology and clinical TB vaccine research.</gtr:impact><gtr:outcomeId>56e06523a7c278.11610279-1</gtr:outcomeId><gtr:partnerContribution>University of Southampton collaborators devised the Reverse Vaccinology approach which led to the selection of the truly novel vaccine candidates for Mycobacterium tuberculosis.
Jenner Institute, Oxford University undertook the animal challenge assays to test the efficacy of the DNA vaccines.</gtr:partnerContribution><gtr:piContribution>Public Health England at Porton Down were responsible for amplification of desired vaccine candidates and generating the DNA vaccines.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Jenner Institute</gtr:department><gtr:description>Collaborators on the 'TB subunit vaccines' project</gtr:description><gtr:id>1AF21223-7F75-4581-9016-48BFDB655164</gtr:id><gtr:impact>Applications for follow-on funding have been made - these were not successful but future funding will be sought.
Presentations of the research so far have been made.
The collaboration is multi-disciplinary in the fields of bioinformatics, pre-clinical vaccinology and clinical TB vaccine research.</gtr:impact><gtr:outcomeId>56e06523a7c278.11610279-2</gtr:outcomeId><gtr:partnerContribution>University of Southampton collaborators devised the Reverse Vaccinology approach which led to the selection of the truly novel vaccine candidates for Mycobacterium tuberculosis.
Jenner Institute, Oxford University undertook the animal challenge assays to test the efficacy of the DNA vaccines.</gtr:partnerContribution><gtr:piContribution>Public Health England at Porton Down were responsible for amplification of desired vaccine candidates and generating the DNA vaccines.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biomedical Primate Research Centre</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Parasitology</gtr:department><gtr:description>Generation of human monoclonal antibodies against malarial antigens</gtr:description><gtr:id>7826565B-9F70-4F50-A458-32EB4739A10D</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>56a62ed986ac92.65964472-1</gtr:outcomeId><gtr:partnerContribution>Support in the analysis of adhesion blocking and reversing properties of recombinant human monoclonal antibodies</gtr:partnerContribution><gtr:piContribution>Provision of recombinant human monoclonal antibodies specific for domains of PfEMP1</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>QuantuMDx Group Limited</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>QuantuMDx</gtr:description><gtr:id>3E43FCED-D2FC-4A97-A9ED-6366DAF98FE9</gtr:id><gtr:impact>QuantuMDx was to be mostly involved in the last phase of the project when the prototype cartridges had been produced. At the time of project completion this was not ready for the Leishmania cartridge. However, we did evaluate a prototype DNA extraction kit developed by QuantumDx which would simplify the processing of samples.</gtr:impact><gtr:outcomeId>58c6b5e0b4a929.15497169-1</gtr:outcomeId><gtr:partnerContribution>QuantuMDx provided the novel platform and cartridges and the SOPs used previously for other indications.</gtr:partnerContribution><gtr:piContribution>LSHTM role was to provide parasite material for use in the QuantuMDx platform device. This involved generating inocula of known number to generate Proof of Principle data in the new technology (a point-of-care diagnostic platform for Leishmania).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Research &amp; Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Drug Discovery Project to develop combination partners targeting the respiratory chain of Mycobacterium tuberculosis</gtr:description><gtr:id>79720004-4B20-4F2B-B7B5-4DCE4DA12894</gtr:id><gtr:impact>No outputs as yet</gtr:impact><gtr:outcomeId>56ddabeac87457.42273105-1</gtr:outcomeId><gtr:partnerContribution>Janssen have provided Materials e.g. bedaquiline. Discussions are taking place for a formal partnership and funding by Janssen of project as well as exclusive licensing of LSTM IP to Janssen.</gtr:partnerContribution><gtr:piContribution>Novel strategy to improve the efficacy of bedaquiline and NCE</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Godrej Consumer Products Limited</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>India-UK Industry partnership</gtr:description><gtr:id>A7E488E0-B6F1-45B4-907F-77DAF84EE586</gtr:id><gtr:impact>Outcome:
1. application for joint MRC CiC award in 2015 to develop resistance diagnostics 
2. Visit planned by Director of LSTM to Godrej headquarters for high level discussions on LSTM-Godrej partnership options</gtr:impact><gtr:outcomeId>56dd588e3afbd0.19452092-1</gtr:outcomeId><gtr:partnerContribution>Godrej set up meetings in Mumbai for reserach and training discussions, and intriductions to senior management.</gtr:partnerContribution><gtr:piContribution>Presented research and training opprtunities for LSTM-Godrej partnership in the vector control arena. Led to joint applications for MRC CiC award and signing of CDA to pursue technology development optiions</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Blueberry Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel antibiotic nano formulations</gtr:description><gtr:id>E590E644-147E-474C-88B4-E671AB7CABCA</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56ddadb0dfcfd8.01285821-1</gtr:outcomeId><gtr:partnerContribution>nano-formulation expertise and materials</gtr:partnerContribution><gtr:piContribution>Imaging and PK-PD platform to screen novel antibiotic formulations against Salmonella</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Elisha Systems Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ELISHA</gtr:description><gtr:id>205D25AA-02E6-4025-BF32-AB70B827862D</gtr:id><gtr:impact>Preproposals submitted to BBSRC and MRC GCRF 2016 funding call.</gtr:impact><gtr:outcomeId>57dbb82a579920.98706967-1</gtr:outcomeId><gtr:partnerContribution>Contntributed technical input for joint funding applications</gtr:partnerContribution><gtr:piContribution>Developed from Adhiron MRC CiC networking meeting in Leeds. Collaborated in preparing MRC and BBSRC GCRF applications for IQK development.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eisai Ltd</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>E209 - New Antimalarial Drug</gtr:description><gtr:id>3D533FD0-B57C-408F-BA45-C59B82117957</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56c5b54775c243.01747958-1</gtr:outcomeId><gtr:partnerContribution>Formal preclinical evaluation</gtr:partnerContribution><gtr:piContribution>Invention of the lead molecule and carrying out of initial biology of a new antimalarial drug.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epistem</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Epistem for the development of a prototype HIV/TB integrated cartridge</gtr:description><gtr:id>79916236-380F-4291-8F60-A6B861BCD59A</gtr:id><gtr:impact>The output of this project is the joint development of a prototype HIV/TB integrated cartridge in order that funding from other donors can be leveraged for continued product development and evaluation. This would include the quantification of viral load, and further investigation into TB drug resistance markers (isoniazid). LSTM gained major experience with diagnostic development, HIV culturing and long term collaboration with Epistem, including matched funding for the project.
Further we aimed to collaborate with our industrial partner Epistem to test sensitivity, specificity, biosafety and development studies in Nigeria of the Mark I cartridge in development.</gtr:impact><gtr:outcomeId>56decf609edb96.90164260-1</gtr:outcomeId><gtr:partnerContribution>Primers and probes will be designed on a high copy number gene target in collaboration with Epistem's team in Manchester. 
Conduct testing of Epistem's integrated cartridge on TB isolates in Cat 3 facilities. Including biosafety evaluation of specimen handling and Limit of Detection testing.</gtr:partnerContribution><gtr:piContribution>After review of the literature and identification of international databases, LSTM conducted a target selection for HIV amplification and the design of prototype reagents.
Set up of HIV culture at LSTM including HIV-1 and HIV-2.
'Wet reagents' for prototype primers will be tested on cultured samples of HIV from both HIV-1 and HIV-2. Limits of Detection will be calculated. Specificity of primer sets will be assessed by testing samples of Streptococcus pneumoniae and influenza in sputum and hepatitis B and Epson Barr Virus in blood.
Pilot collection of clinical samples from Zankli Medical Centre, Nigeria. Pilot samples will be collected from HIV and TB suspects.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Confidence in Concept (CiC) Tropical Infectious Disease Consortium Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>370DB2E8-682A-4B1E-BAA8-80E771EEFAB4</gtr:id><gtr:impact>MRC Confidence in Concept (CiC) Tropical Infectious Disease Consortium meeting was held in Oxford on Wednesday 10th February 2016. Attendees included representatives from The MRC, Public Health England, SMEs and several academic Institutions accross the UK. Work on vaccine dose reduction was presented as one of &amp;quot;Showcase presentations&amp;quot; of projects funded by the MRC CiC scheme.

Aims of the meeting were: 
- To showcase breadth and depth of projects, highlighting those that have already made significant progress/success
- To discuss further opportunities for cross-institute collaborations
- For the MRC to inform awardees and interested parties of pathways to further funding (e.g. DPFS/TSB etc)
- Foster interaction with SMEs that may be interested in working in partnership with the Consortium to facilitate product funding/development</gtr:impact><gtr:outcomeId>56bcb09bec79e6.09470761</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.jenner.ac.uk/_asset/file/mrc-cic-tropical-infectious-disease-consortium-poster-10-feb-16-v2.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FA2DFDF3-D2CA-4E75-B7A3-AE71E474FB20</gtr:id><gtr:impact>Talk on Malaria, Ebola and Vaccines to 130 Year 6 pupils followed by questions afterwards.</gtr:impact><gtr:outcomeId>56b212a8b8ca50.87242152</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at the &quot;Closing the Global Health Divide through Partnership Driven Innovation Meeting&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9FC32795-A61A-485E-A3E7-FCB42FD11936</gtr:id><gtr:impact>The event represented a collective call for greater cross-border and cross-sector collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases that disproportionally affect the poorest of the poor in developing countries. A series of presentations and interactive panels articulated the need for partnerships in global health and explored the challenges associated with R&amp;amp;D for infectious diseases.</gtr:impact><gtr:outcomeId>56b217b99adc11.71209681</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Liverpool Life Sciences UTC, Malaria Seminar Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A93D0278-947B-450E-9867-27ADB87CEDA5</gtr:id><gtr:impact>22nd Oct 2014, Liverpool Life Sciences UTC, Malaria Seminar Day. &amp;quot;Malaria: of mosquitoes and men&amp;quot;. &amp;gt;100 pupuils from UTC attended a Malaria Seminar Day at U of Liverpool. There was keen interest in the topic with tweets and students following up with visits to the Vector Department to discuss posters and projects.</gtr:impact><gtr:outcomeId>56dd5b39ae9e38.97332086</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference &quot;Mosquito-borne viruses: can we build on commonalities to pre-empt the future?&quot; the Wellcome Trust, London</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BABE5F0A-1A54-4D07-BF3C-4EC6B71C9D2C</gtr:id><gtr:impact>Conference titled &amp;quot;Mosquito-borne viruses: can we build on commonalities to pre-empt the future?&amp;quot; on 5-7 October 2016, London. A joint WHO-Wellcome Trust three-day meeting on mosquito-borne viral diseases; I was a session chair and presenter.

The Wellcome Trust hosted this WHO conference in London, UK on October 5th to 7th 2016. The meeting covered a variety of topics concerning mosquito born viruses, including vaccines, vector control, medicines and blood products, diagnostics, regulatory issues, and yellow fever. An executive summary is now available on request and an official synopsis of this meeting will be published in early 2017.

Attendance by and conversations with DfID staff, are believed to have influenced the prioritising of Aedes-borne arboviral diseases in the 2017 subsequent funding call.</gtr:impact><gtr:outcomeId>58c18cad7b3444.06431966</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Discussion forum at the House of Commons</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1774662A-44B3-4D7D-9AC9-E1EDBE374AFB</gtr:id><gtr:impact>Dengue: falling between the cracks: a high-level roundtable discussion with Dods and Malaria Consortium, Hosted by Imran Hussain MP at the House of Commons, Wednesday 30th November 2016</gtr:impact><gtr:outcomeId>58c18e1e1202d8.06630692</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CEB24762-89C1-402F-9DE8-7190B7CF69FE</gtr:id><gtr:impact>Presentation to Bill Gates (BMGF), George Osborne (Chancellor for the Exchequer, UK Gov), Justine Greening (DfID, UK), Industry heads and media reps, during institution visit to announce the &amp;pound;3billion Ross Fund.</gtr:impact><gtr:outcomeId>56ba06e86f74b3.28862910</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk Rotary Club Heswall</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>53825F88-69FD-49B7-BE01-4F5B3215D2FE</gtr:id><gtr:impact>Talk given to Rotary club Members about the reasons behind repeated infection with malaria. Sparked debate and iterest and helped audience to understand why it is so difficult to eradicate the disease</gtr:impact><gtr:outcomeId>56a752eb407cd1.29974859</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1415000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Diagnostic tools for poverty-related diseases</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>CE7A4EE8-CBC2-4D50-B9A4-4C4D862D5E48</gtr:id><gtr:outcomeId>56de9e406ac3d9.91851207</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>51813</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Human Nutrition Research Unit</gtr:department><gtr:description>MRC CiC Oxford Fund</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6619356E-E9CC-4E32-9ECA-15D249EE28BA</gtr:id><gtr:outcomeId>58bfd4764dfd52.17415491</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98932</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathfinder Award</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>109744/Z/15/Z</gtr:fundingRef><gtr:id>BB0B2D8E-2C16-4CD2-9088-CB8538A5D9C0</gtr:id><gtr:outcomeId>56bc91d59cd589.81782341</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>104000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE studentship</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7DB3E940-B8C8-4D10-A923-178F8040C835</gtr:id><gtr:outcomeId>5825c1c77649a6.09959338</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2474741</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Collaborative Award</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>69148FFE-E32C-41AD-A979-CC8DE09C21B7</gtr:id><gtr:outcomeId>56ba0446f096c6.51281555</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20775374</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>JPY</gtr:currCode><gtr:currCountryCode>Japan</gtr:currCountryCode><gtr:currLang>ja_JP</gtr:currLang><gtr:description>GHIT &amp;quot;E209 a tetraoxane based rapidly acting antimalarial&amp;quot;</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Global Health Innovative Technology Fund</gtr:fundingOrg><gtr:fundingRef>G2015-120R1</gtr:fundingRef><gtr:id>2266F9B4-010B-4282-BE8D-25E47395D535</gtr:id><gtr:outcomeId>56c5b75248ed43.92962942</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>MRC</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0F45E268-8DB6-4114-B448-87C5EB1C8E0E</gtr:id><gtr:outcomeId>58ca68f765b1e5.26321995</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000045</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Invited grant proposal</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1159078</gtr:fundingRef><gtr:id>2EF352B2-3FF9-43F6-AC9D-420FB3E5B641</gtr:id><gtr:outcomeId>58c188d7d86396.87545333</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel insecticide-treated bed net (LLIN) designs to permit safe delivery of non-pyrethroid insecticides rendering the bed nets effective against insecticide resistant mosquitoes.</gtr:description><gtr:grantRef>MC_PC_13069</gtr:grantRef><gtr:id>65183085-2408-4A6F-BD9F-80950957BCAA</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56ba07f0b74476.66951905</gtr:outcomeId><gtr:patentId>International Patent Application No PCT/GB2014/053154</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Mosquito net assembly</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel design of Combination Therapy for Tuberculosis drugs based on the inhibition of respiratory inhibitors.

TheUK patent application has been submitted and the number is 1522232.6
The patent has been submitted and Janssen Pharmaceutica are interested in an exclusive licence - discussion are underway</gtr:description><gtr:grantRef>MC_PC_13069</gtr:grantRef><gtr:id>88242B8A-3B15-4994-A816-5239922E515E</gtr:id><gtr:impact>The patent has been submitted and Janssen Pharmaceutica are interested in an exclusive licence</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56dda438aec909.61067804</gtr:outcomeId><gtr:patentId>UK Patent application 1522232.6</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Combination Therapy</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>? UK management committee member for COST Action CM1307, 'Targeted chemotherapy towards diseases caused by endoparasites&amp;quot; - 2014- to date</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>317B3555-5068-4B52-8AD4-21A530439DF5</gtr:id><gtr:outcomeId>56ddaeb04727c0.83647859</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.costcm1307.org/CM1307/Home.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EVI European Vaccine Workshop</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>94CF64E8-72AB-433D-A433-E60FF973458A</gtr:id><gtr:outcomeId>56e0304f19ecf2.75089531</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/26431986</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Macrofilaricide Drug Accelerator (MacDA)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>70C97825-D3FC-42CA-83DB-FB236CC93774</gtr:id><gtr:outcomeId>56c5baf6710884.05438375</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External advice to major funder with regard to antimalarial drug discovery projects</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A921EAF3-1B26-4994-84B7-C4AEB57B65E1</gtr:id><gtr:outcomeId>58221de4d4eb66.30605490</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the MMV External Scientific Advisory Board 2017 to date</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>29E0F391-CA53-4ADB-B044-7F2B955F46EE</gtr:id><gtr:outcomeId>58c7ce99550d66.70277946</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External Scientific Advisory Board Member for the German Centre for Infection Research</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>7170D745-64E6-4DF8-9E63-0EDC9AEC7516</gtr:id><gtr:outcomeId>56b21dad3e2558.73697929</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Ongoing Syngenta chemical library being assessed for in vitro anti malarial activity</gtr:description><gtr:id>74A0C9E0-1557-45DE-9D66-772B3F344CE0</gtr:id><gtr:impact>Will generate starting points for drug discovery programmes</gtr:impact><gtr:outcomeId>5460d6fff410b7.17626336</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Syngenta antimalarial hits</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>The cartridge safety standards were reviewed, which led to a review of procedures and enhancement of the bio-safety of the cartridge.</gtr:description><gtr:id>0685D072-8DDD-4A33-99F5-0BDAB78898E4</gtr:id><gtr:impact>We are currently conducting a new safety evaluation of the cartridge</gtr:impact><gtr:outcomeId>56deb84d357651.44750343</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>safety assessment of the new Genedrive tuberculosis cartridge and reported back to the SME Epistem</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Sequences of variable region of immunoglobulin genes from individuals living in malaria endemic areas. Enriched for variable immunoglobulin region specific for PfEMP1.</gtr:description><gtr:id>3A455EC8-2211-49DF-841B-724973C3A465</gtr:id><gtr:impact>The data once deposited into a publicly available database will allow comparison with sequences specific for other antigens</gtr:impact><gtr:outcomeId>56a7659ea9ed36.80036246</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>variable immunoglobulin gene region</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We evaluated the limits of detection of the Genedrive tuberculosis cartridge and reported back to the SME Epistem.</gtr:description><gtr:id>CAF7310A-7F74-4B16-9D53-9F36A7B6B552</gtr:id><gtr:impact>This led to epistem changing the design of the cartridge to process a higher volume of sputum to increase the number of bacilli identified. A new cartridge is being evaluated in LSTM.</gtr:impact><gtr:outcomeId>56deb915891435.41739771</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>limits of detection of the Genedrive tuberculosis cartridge</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Background

The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a number of promising single and combined therapies reach the late stages of development. A key drug development challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of iterative QSAR (quantitative structure-activity and relationships) cycles of medicinal chemistry and biological testing will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements available from in vitro studies can be used for such clinical predictions. However, these predictions often require bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, therefore, not during the pre-clinical development phase when such decisions need to be made.

Methods

An internet-based tool has been developed using STELLA&amp;reg; software. The tool simulates multiple differential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom compounds.

Results

The results of simulations obtained from OptiMal-PK were compared to a previously published and validated mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published clinical parasitological clearance activities for these existing therapies.

Conclusions

OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the predicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of a compound are most important to the clinical performance of a new chemical entity and how partner drugs could potentially improve the activity of existing therapies.</gtr:description><gtr:id>0E8E48E6-1CCC-43FE-A941-65DA86420A78</gtr:id><gtr:impact>The software has been used by a number of users for both teaching and research purposes. The use of the model has lowered the number of animal experiments in my laboratory but it is difficult to estimate how many in vivo experiments it has reduced externally. We are currently working to promote the on-line tool.</gtr:impact><gtr:outcomeId>58c6983c6c13b7.44669497</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://optimalpk.lstmed.ac.uk</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The research aims to test the hypothesis that candidate antigens predicted in a previously published reverse vaccinology (RV) approach (Bowman et al., 2011) will exhibit sufficient antigenicity for incorporation into subunit vaccines for Mtb. Additional bioinformatics analyses such as predicted expression and analysis of transmembrane domains were performed in order to generate a short-list of 6 candidate genes which were formulated as DNA vaccines. This was achieved using the Invitrogen Gateway cloning system to insert the genes into a modified pVAX plasmid. After confirmation that the sequence was correct, the plasmids underwent amplification, purification and transfection studies were carried out which proved that the proteins were expressed in eukaryotic (hamster) cell lines. Further quality control checks were also completed (i.e. restriction digests) which confirmed the correct, complete desired sequences had been inserted into the DNA vaccine constructs. The DNA vaccine solutions were then diluted to the appropriate concentration for mouse experiments to evaluate the protective efficacy of the vaccines against Mtb challenge. The first challenge experiment has been completed and compared 6 plasmid DNA vaccines with a BCG vaccinated control group and an untreated group (n=8 per group). Protection was determined by the ability to reduce the number of viable bacteria in the lungs and spleens of animals, measured at 4 weeks post- aerosol challenge with M. tuberculosis. Two of the candidates showed efficacy by reducing the bacterial counts in the lungs compared to the un-vaccinated controls. A repeat study on up to 3 candidates which show protection was initiated in January 2016 for completion in April 2016.</gtr:description><gtr:id>56B42206-E84C-467A-8784-10D59BA55625</gtr:id><gtr:impact>If the methodology is successful at predicting efficacious vaccine candidates for Mycobacterium tuberculosis the impact will be a research tool which will improve the ability to identify novel vaccine candidates for TB disease and for other important bacterial pathogens.

Specifically the TB vaccine candidates identified in this award could be incorporated into suitable delivery systems for further development towards an improved vaccine for TB.</gtr:impact><gtr:outcomeId>56e06144b7ad12.86464419</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>The evaluation of new antigens for subunit vaccines against Mycobacterium tuberculosis.</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>To date, we generated 6 recombinant monoclonal antibodies recognizing at least 2 different variants of the DBLbeta domain of PfEMP1, which mediates adhesion of P. falciparum infected erythrocytes to ICAM-1. Three of these recombinant antibodies react with at least four different DBLbeta variants and can be considered cross-reactive. Importantly, these antibodies react with the native protein expressed on the surface of infected erythrocytes by flow cytometry and in agglutination assays.</gtr:description><gtr:id>58910C12-8C76-4AB5-9ACC-54028DF03A33</gtr:id><gtr:impact>The characterisation of recombinant monoclonal antibodies is still in early stages. If one or more of these antibodies reverse adhesion of infected erythrocytes to ICAM-1, their use as an adjunct therapy for severe malaria can be investigated.
In addition, both variant-specific and variant-transcending antibodies will be useful tools for other researchers who investigate the biology of or the pathology mediated by expression of PfEMP1 on infected erythrocytes.</gtr:impact><gtr:outcomeId>56a7638f2ef8d6.28375267</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Recombinant human monoclonal antibodies against the DBLbeta domain of PfEMP1</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DDT binding adhirons developed that can be used to track DDT.</gtr:description><gtr:id>3DDE3059-4EE6-44A6-8B05-DAD24CD06336</gtr:id><gtr:impact>Still in early phase IP protection</gtr:impact><gtr:outcomeId>56dd555a482429.26709732</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DDT-Adhiron</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DDT-hapten; new biotinylated DDT engineered for biopanning</gtr:description><gtr:id>51C5CD56-AA8B-4540-A49F-F04D757F3684</gtr:id><gtr:impact>Used to isolate DDt-Adhirons, diagnostic for DDT detection in development</gtr:impact><gtr:outcomeId>56dd5451efb961.05360884</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DDT-Hapten</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Activation and amplification of antigen-specific memory B cells through in vitro culture of memory B cells, autologous T cells and antigen followed by single cell sorting of activated B cells</gtr:description><gtr:id>E9B9BB19-23E5-40E5-8F71-B852BBDAE423</gtr:id><gtr:impact>The method is useful when the number of memory B cells specific for a given antigens is low for instance when the volumne of blood available from a volunteer is small or infection occurred several years ago.</gtr:impact><gtr:outcomeId>56a764a5356c94.83030731</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Amplification of antigen-specific memory B cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6020FB42-EA1C-4BB4-A38A-AD7F73871C88</gtr:id><gtr:title>2-Pyridylquinolone
 antimalarials with improved antimalarial activity and physicochemical properties</gtr:title><gtr:parentPublicationTitle>MedChemComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b7d9a6884c2f596793e573ed8cbe50"><gtr:id>d8b7d9a6884c2f596793e573ed8cbe50</gtr:id><gtr:otherNames>Charoensutthivarakul S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2040-2503</gtr:issn><gtr:outcomeId>56b1f1a3c08cb4.35220632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>638A77CB-CAC4-495D-8122-0F11B01CB88B</gtr:id><gtr:title>Corrigendum: A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>58c7cda72f7a50.40072733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B96CFDB8-5F2C-4E7F-B53D-E8733D5048DA</gtr:id><gtr:title>Influence of theGene on In Vitro Sensitivities of Piperaquine in Thai Isolates of.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/690909a391a0c1aab3ba74b8b327a637"><gtr:id>690909a391a0c1aab3ba74b8b327a637</gtr:id><gtr:otherNames>Mungthin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>58c7cda78786e3.48202906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C803BBB-1966-47EA-A3BA-E27597ACD276</gtr:id><gtr:title>OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3511efcc710829c2226c3891942d74"><gtr:id>1e3511efcc710829c2226c3891942d74</gtr:id><gtr:otherNames>Aljayyoussi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>582445d93f6472.83443694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>385C9691-075C-4791-A2D0-280DE17374A9</gtr:id><gtr:title>Next generation vaccines: single-dose encapsulated vaccines for improved global immunisation coverage and efficacy.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33b6942c9ff0d129d7b03f1c51e44bb9"><gtr:id>33b6942c9ff0d129d7b03f1c51e44bb9</gtr:id><gtr:otherNames>Walters AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>58bfd35a95e8e0.74667266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F87BA492-D207-48AE-BB77-C0800F3AA622</gtr:id><gtr:title>A novel video-tracking system to quantify the behaviour of nocturnal mosquitoes attacking human hosts in the field.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d46eaeda9d96e917788a4f3e7d5bd4b5"><gtr:id>d46eaeda9d96e917788a4f3e7d5bd4b5</gtr:id><gtr:otherNames>Angarita-Jaimes NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>585d50b6a656c6.17144030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90739C14-EF61-4168-ACBF-373D92242649</gtr:id><gtr:title>Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5211771b9988c81aea61d371b9ad55e4"><gtr:id>5211771b9988c81aea61d371b9ad55e4</gtr:id><gtr:otherNames>McConville M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>56b1f1003b46c4.21082368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DE828FA-027A-4DF9-85CA-E76B9FDCCBA5</gtr:id><gtr:title>Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e4ebb681ccf6798567dcd0ff136045"><gtr:id>01e4ebb681ccf6798567dcd0ff136045</gtr:id><gtr:otherNames>T?r?k ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>58c7cda7b071f0.39970043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B88CD2C9-DB01-4DB3-BBF4-7B6C5A48DA2A</gtr:id><gtr:title>A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>582445d8e08c69.72871232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74B2F6EA-2A97-4044-9C96-336516B4A200</gtr:id><gtr:title>A validated bioluminescence-based assay for the rapid determination of the initial rate of kill for discovery antimalarials.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cfc0d6f124198059af525f598f094aa"><gtr:id>2cfc0d6f124198059af525f598f094aa</gtr:id><gtr:otherNames>Ullah I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58c67a9bc89b21.81770930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD790DA5-68DE-465B-9DA2-A4BE9AA675BC</gtr:id><gtr:title>Aedes Mosquitoes and Aedes-Borne Arboviruses in Africa: Current and Future Threats.</gtr:title><gtr:parentPublicationTitle>International journal of environmental research and public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30e6be939d5d276a3db31150a3bf7081"><gtr:id>30e6be939d5d276a3db31150a3bf7081</gtr:id><gtr:otherNames>Weetman D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1660-4601</gtr:issn><gtr:outcomeId>5aa26dd4cc96f2.67900425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43F54757-CA50-4536-9973-5F3CD544F10C</gtr:id><gtr:title>Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology.</gtr:title><gtr:parentPublicationTitle>International journal of molecular sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc022eda81924ee5e90d188cafdfde28"><gtr:id>bc022eda81924ee5e90d188cafdfde28</gtr:id><gtr:otherNames>Heinson AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1422-0067</gtr:issn><gtr:outcomeId>59bbaebe6edef7.62717002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>104BFDAE-D487-4C05-9E8E-EFDF46858758</gtr:id><gtr:title>Infrared video tracking of Anopheles gambiae at insecticide-treated bed nets reveals rapid decisive impact after brief localised net contact.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fb27f79cf7a5d9fc3474ee867d9fda8"><gtr:id>9fb27f79cf7a5d9fc3474ee867d9fda8</gtr:id><gtr:otherNames>Parker JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>59c3c3e561e192.58875391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ED569F6-6E22-4D78-847C-ACD75205B580</gtr:id><gtr:title>Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56dda541350093.95496490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7517AC16-2B71-4CD8-9A36-78BA22FA8EF9</gtr:id><gtr:title>A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0044-8249</gtr:issn><gtr:outcomeId>582445d92037f5.81178827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEDE524A-04C9-490A-BD38-E4D891E86CB9</gtr:id><gtr:title>Host-seeking activity of a Tanzanian population of Anopheles arabiensis at an insecticide treated bed net.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bffee79a04cb6eae41f3de231b45829"><gtr:id>9bffee79a04cb6eae41f3de231b45829</gtr:id><gtr:otherNames>Parker JEA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>59c3c41c6acac6.54634510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F67B3C6F-7C43-4ED3-BA1D-9C876AAF99FF</gtr:id><gtr:title>A simple breath test for tuberculosis using ion mobility: A pilot study.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88ce30a76d276e0ea052acc81bb19e3f"><gtr:id>88ce30a76d276e0ea052acc81bb19e3f</gtr:id><gtr:otherNames>Sahota AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>585d6b1c51b609.97404561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAAFD228-CF15-4399-8F3B-703DFE978CFB</gtr:id><gtr:title>A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06c05b3620f7d7cdab1f4b38cdaeaef"><gtr:id>a06c05b3620f7d7cdab1f4b38cdaeaef</gtr:id><gtr:otherNames>O'Neill PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>56b1f123e36193.28350084</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13069</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>